AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Status:
RECRUITING
Trial end date:
2029-06-14
Target enrollment:
Participant gender:
Summary
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL.